Comparative Pharmacology
Head-to-head clinical analysis: ATAZANAVIR SULFATE versus LEXIVA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATAZANAVIR SULFATE versus LEXIVA.
ATAZANAVIR SULFATE vs LEXIVA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atazanavir is an azapeptide HIV-1 protease inhibitor. It selectively inhibits the virus-specific processing of viral Gag and Gag-Pol polyproteins in HIV-1 infected cells, preventing formation of mature virions.
Fosamprenavir is a prodrug of amprenavir, a protease inhibitor (PI) that competitively inhibits HIV-1 protease, preventing cleavage of viral Gag-Pol polyprotein, resulting in immature, non-infectious viral particles.
300 mg orally once daily with ritonavir 100 mg orally once daily, or 400 mg orally once daily without ritonavir (when used alone).
1400 mg orally twice daily (with ritonavir 100 mg) or 1400 mg orally once daily (with ritonavir 100 mg and cobicistat 150 mg). For treatment-naïve patients, 1400 mg orally once daily with ritonavir 100 mg or cobicistat 150 mg.
None Documented
None Documented
Terminal elimination half-life: ~6.5 to 7 hours; supports once-daily dosing.
Terminal elimination half-life is 2.8 to 5.7 hours; with ritonavir boosting, half-life increases to 7-10 hours, allowing once-daily dosing.
Biliary/fecal: ~79% as unchanged drug; renal: ~13% (including <1% unchanged).
Renal (approximately 82% in urine, with 14% as parent drug and 68% as metabolites); fecal (approximately 16%, with 7% as parent drug).
Category C
Category C
Protease Inhibitor
Protease Inhibitor